Deutsche Bank AG Increases Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Deutsche Bank AG boosted its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 46.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 34,082 shares of the company's stock after buying an additional 10,839 shares during the quarter. Deutsche Bank AG owned approximately 0.07% of Amphastar Pharmaceuticals worth $1,265,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in AMPH. Smartleaf Asset Management LLC grew its holdings in shares of Amphastar Pharmaceuticals by 222.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock worth $26,000 after purchasing an additional 493 shares during the last quarter. Parkside Financial Bank & Trust raised its stake in Amphastar Pharmaceuticals by 806.5% during the fourth quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock worth $36,000 after purchasing an additional 871 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of Amphastar Pharmaceuticals by 43.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock valued at $43,000 after acquiring an additional 348 shares during the period. Huntington National Bank grew its holdings in Amphastar Pharmaceuticals by 36.9% during the 4th quarter. Huntington National Bank now owns 1,340 shares of the company's stock worth $50,000 after acquiring an additional 361 shares in the last quarter. Finally, TD Private Client Wealth LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 22.7% in the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock valued at $78,000 after buying an additional 388 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company's stock.

Wall Street Analysts Forecast Growth

AMPH has been the subject of several recent research reports. Wells Fargo & Company dropped their target price on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. Piper Sandler dropped their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st. JPMorgan Chase & Co. restated a "neutral" rating and issued a $30.00 price target (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Amphastar Pharmaceuticals currently has an average rating of "Hold" and an average target price of $32.33.

Insider Transactions at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at $2,681,377.02. The trade was a 4.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last 90 days, insiders sold 5,231 shares of company stock valued at $142,752. 27.10% of the stock is currently owned by insiders.

Amphastar Pharmaceuticals Price Performance

NASDAQ:AMPH traded down $0.27 during trading hours on Wednesday, reaching $25.26. The company had a trading volume of 476,324 shares, compared to its average volume of 481,250. The stock has a 50-day moving average of $25.08 and a two-hundred day moving average of $32.60. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The firm has a market capitalization of $1.20 billion, a PE ratio of 8.42, a PEG ratio of 2.19 and a beta of 0.78. Amphastar Pharmaceuticals, Inc. has a one year low of $22.64 and a one year high of $53.96.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.